omniture
logo
Search
中山康方生物医药有限公司
Media Room

Latest News

rss

New Drug Application for Cadonilimab (PD-1/CTLA-4 Bi-Specific Antibody) for the Treatment of Relapsed or Metastatic Cervical Cancer Accepted by NMPA

HONG KONG, Sept. 23, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Nat...

2021-09-24 09:18 3335

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China

HONG KONG, Aug. 5, 2021 /PRNewswire/ -- Akeso, Inc. (9926.HK, the "Company" or "Akeso") announced t...

2021-08-06 09:39 28382

CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia

HONG KONG, July 12, 2021 /PRNewswire/ -- Akeso, Inc. is pleased to announce that, CD47 monoclonal a...

2021-07-13 09:06 1950

Akeso Awarded as 2021 "Most Honored Company" by Institutional Investor

HONG KONG, June 30, 2021 /PRNewswire/ -- Akeso, Inc. ("Akeso" or the "Company", stock code: 9926.HK...

2021-06-30 16:00 13267

Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States

HONG KONG, May 24, 2021 /PRNewswire/ -- On May 24, 2021, Akeso, Inc. (HKEx: 9926.HK) announced that...

2021-05-24 18:17 2809

ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted FDA Fast Track Designation for Recurrent and Metastatic Cervical Cancer

LOS ANGELES, Aug. 13, 2020 /PRNewswire/ -- Akeso, Inc (9926.HK) - a biopharmaceutical company dedic...

2020-08-13 20:07 5497

Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee

LOS ANGELES, June 24, 2020 /PRNewswire/ -- Akeso, Inc. ("Akeso", 9926.HK) announced the appointment...

2020-06-24 12:55 7232
12345